Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13058656 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL4961276 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL5885617 | 0.89 | CTSK (0.53) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL8098620 | 0.89 | CTSL (0.55) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL1701577 | 0.89 | CTSL (0.55) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL13724915 | 0.88 | CASP1 (0.57) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL13724913 | 0.88 | CASP1 (0.57) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL16847591 | 0.87 | CTSL (0.62) | CTSKCTSLCTSBCTSS | |
| SCHEMBL19017976 | 0.86 | CTSK (0.55) | CTSKCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL7220623 | 0.86 | CTSL (0.67) | CTSKCTSLCTSBCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | CTSK 2426/4885CTSL 832/4885CTSB 2517/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | CTSK 2428/4885CTSL 829/4885CTSB 2527/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | CTSK 2767/4885CTSL 1016/4885CTSB 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.